BCRX today
$7.61-$0.07 (-0.91%)close Nov 13, 2026Trend
DailyDowntrend (starting)
4 hourStrong Bearish
1 hourSymmetric Triangle
15 minBullish
5 minSymmetric Triangle
Daily trend turns up above $11.31
Key levels
Resistance$8.11
Resistance$7.74
Support$7.38
Support$6.71
Latest news & SEC filings
AnalystWedbush kept its Outperform rating on BioCryst Pharmaceuticals (BCRX) and lowered its price target to $17 from $20.
All BCRX news →About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a biotechnology company that creates and sells treatments for hereditary angioedema and additional uncommon conditions. Its lead product is ORLADEYO, a pill taken by mouth each day that helps prevent hereditary angioedema attacks, and it also markets an intravenous influenza drug in the United States, Canada, Australia, Japan, Taiwan and Korea. The company sells directly in the United States and through partners across Latin America, Asia and Europe, and it is developing further therapies for rare conditions.
Based on the company's 10-K filed Feb 26, 2026.
Nasdaq · Healthcare
BIOCRYST PHARMACEUTICALS INC (BCRX)
What Is the Price Target for BCRX?
SEPT Low Target
$11.00
SEPT Mid Target
$16.00
SEPT High Target
$32.00
Analyst Consensus
$16.00
Is BCRX a Buy or Sell Right Now?
Thesis
- •Revenue growing 94.1% YoY with ACCELERATING trend — accelerating momentum.
- •SEC filings signal active product innovation — 2 new product/expansion keywords detected in 10-K. R&D investment stable.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for BCRX.
Start Free Trial →Is BCRX Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$16.00
19
Moat Score
NONE
6/9
Piotroski Score
2.0
Altman Z-Score
What Is Smart Money Doing with BCRX?
Insider Signal
NEUTRAL
0 buys / 1 sells (90d)
Congress Signal
BUYING
3 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Stonehouse Jon P | director | Buy | 644 | $6K | Aug 31, 2026 |
| Milne Jill C. | director | Buy | 1,288 | $12K | Aug 31, 2026 |
| MILANO VINCENT | director | Buy | 1,159 | $11K | Aug 31, 2026 |
| McKee Amy E | director | Buy | 644 | $6K | Aug 31, 2026 |
| Frank Steven | director | Buy | 1,288 | $12K | Aug 31, 2026 |
| Milne Jill C. | director | Buy | 15,294 | - | Jun 11, 2026 |
| Galson Steven K | director | Buy | 15,294 | - | Jun 11, 2026 |
| LEVIN ALAN G | director | Buy | 15,294 | - | Jun 11, 2026 |
| Frank Steven | director | Buy | 15,294 | - | Jun 11, 2026 |
| SANDERS MACHELLE | director | Buy | 15,294 | - | Jun 11, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →BCRX Growth Story
Revenue YoY
94.1%
3yr Revenue CAGR
47.8%
EPS Growth YoY
381.4%
FCF Growth YoY
749.0%
Revenue Trend
ACCELERATING
Dark Pool Trades for BCRX
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for BCRX, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 22:21:16 | $7.61 | 6,966 | $$53K | SELL |
| 21:00:39 | $7.61 | 1,552 | $$12K | SELL |
| 21:00:39 | $7.61 | 1,566 | $$12K | SELL |
| 21:00:39 | $7.61 | 1,384 | $$11K | SELL |
| 21:00:39 | $7.61 | 5,740 | $$44K | SELL |
5 dark pool trades shown · $$131K preview volume
Real-time institutional flow, block trades, and net positioning
Options Flow for BCRX
PREVIEWSEPT Investing provides real-time options flow tracking for BCRX, including unusual sweep detection, block trades, and dealer positioning. Each trade shows strike, expiry, premium, implied volatility, and greek values for informed decision-making.
| Type | Strike | Expiry | DTE | Premium | Size | Trade |
|---|---|---|---|---|---|---|
| CALL | $8 | Nov 20 | 7 | $$30 | 3 | SWEEP |
| CALL | $8 | Dec 18 | 35 | $$25 | 1 | SWEEP |
| CALL | $8 | Dec 18 | 35 | $$50 | 2 | SWEEP |
| CALL | $8 | Dec 18 | 35 | $$25 | 1 | SWEEP |
| CALL | $8 | Dec 18 | 35 | $$25 | 1 | SWEEP |
5 options trades shown · 100% calls
Unusual activity, GEX levels, max pain, and dealer positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for BIOCRYST PHARMACEUTICALS INC (BCRX) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →BCRX — frequently asked questions
What is BCRX stock price today?
BIOCRYST PHARMACEUTICALS INC (BCRX) is at $7.61, down 0.91% (-$0.07) at the Nov 13, 2026 close.
Why is BCRX stock moving today?
Latest BCRX news — Nov 5, 2026: Wedbush kept its Outperform rating on BioCryst Pharmaceuticals (BCRX) and lowered its price target to $17 from $20.
What is the BCRX price target?
The average analyst price target for BCRX is $16.00, ranging from $11 to $32, based on 9 analysts. Latest: JP Morgan maintains on Sep 30, 2026.
What do analysts rate BCRX?
Analyst ratings for BCRX: 0 Buy, 9 Hold, 2 Sell — consensus Hold.
Did BCRX beat earnings?
BCRX last reported on Aug 5, 2026: EPS $0.30 vs $0.15 expected — a beat of 94.6%.
Does BCRX pay a dividend?
BCRX does not currently pay a dividend.
What are BCRX support and resistance levels?
Support: $7.38, $6.71, $6.23. Resistance: $7.74, $8.11, $8.62.
What are insiders doing with BCRX?
Insider activity: NEUTRAL, 0 buys and 1 sells in the last 90 days.
What is the latest news on BCRX?
Nov 5, 2026: Wedbush kept its Outperform rating on BioCryst Pharmaceuticals (BCRX) and lowered its price target to $17 from $20.